Presentation is loading. Please wait.

Presentation is loading. Please wait.

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,

Published byAllen Gyles Carroll Modified over 6 years ago

Similar presentations

Presentation on theme: "Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,"— Presentation transcript:

1 Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt, MBBS, FRCPA, Sean Bydder, MBChB, FRANZCR, Michael Millward, FRACP, Michael Byrne, MBBS, BMed Sci, FRACP, Arthur W. (Bill) Musk, MBBS, MD, MSc, FRACP, FAFOEM, Anna K. Nowak, MBBS, FRACP, PhD  Journal of Thoracic Oncology  Volume 4, Issue 8, Pages (August 2009) DOI: /JTO.0b013e3181ae25bf Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Flow chart of workup and treatment of eligible patients referred for TMT. MDM, multidisciplinary meeting; MPM, malignant pleural mesothelioma; TMT, trimodality therapy; EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Flow chart of patient progression. TMT, trimodality therapy; EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier survival curves of survival after date of diagnosis for EPP group (n = 18) and non-EPP group (n = 18). EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma  Vivek Verma, MD, Christopher A. Ahern,

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma  Vivek Verma, MD, Christopher A. Ahern,
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Similar presentations

Ads by Google